Dupilumab, a fully human monoclonal antibody targeting the IL-4 receptor-α, blocking both IL-4 and IL-13 signaling, is a newly developed agent, and the first targeted treatment to show successful results in early clinical trials for AD [11,24]. Here, IL13 is linked to Alzheimer disease.